Summary
AVDL Chart
Wall Street Analysts See an 81.61% Upside in Avadel (AVDL): Can the Stock Really Move This High?
The consensus price target hints at an 81.6% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Surging Earnings Estimates Signal Upside for Avadel (AVDL) Stock
Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZâ„¢ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ may be clinically superior to the same drug(s) already approved for the same indication, because LUMRYZ may provide a major contribution to patient care due to its once-nightly dosing for patients with IH, a chronic sleep disorder that requires potentially lifelong treatment.
Avadel Pharmaceuticals plc Dividends
Avadel Pharmaceuticals plc Earnings
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 3 Mar 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 31 Jul 2024 Date | | - Cons. EPS | - EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 3 Mar 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 31 Jul 2024 Date | | - Cons. EPS | - EPS |
Avadel Pharmaceuticals plc (AVDL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Avadel Pharmaceuticals plc ever had a stock split?
Avadel Pharmaceuticals plc Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Gregory J. Divis Jr. CEO | NASDAQ (NMS) Exchange | 05337M104 Cusip |
| IE Country | 188 Employees | - Last Dividend | - Last Split | 7 Jun 1996 IPO Date |
Overview
Avadel Pharmaceuticals plc is a biopharmaceutical firm based in the United States, with its headquarters in Dublin, Ireland. Initially founded as Flamel Technologies SA, the company underwent a name change to Avadel Pharmaceuticals plc in January 2017, signaling a new phase in its journey since its incorporation in 2015. The company specializes in developing and delivering pharmaceutical products, focusing on therapies that address unmet medical needs. Avadel Pharmaceuticals plc has carved a niche for itself in the biopharmaceutical industry through its innovative drug development programs and a commitment to improving the lives of patients suffering from various conditions.
Products and Services
- LUMRYZ - This is Avadel Pharmaceuticals plc's lead product candidate, currently in a Phase 3 clinical trial. LUMRYZ is a formulation of sodium oxybate designed to treat excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. By targeting these symptoms, LUMRYZ aims to significantly improve the quality of life for individuals affected by narcolepsy, a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep.
Contact Information
